As the first-ever Medicare drug-price negotiations take shape, Big Pharma-backed Democrats want to limit the number of costly medicines regulators can target.
Democratic Reps. Scott Peters (Calif.), Wiley Nickel (N.C.), Josh Gottheimer (N.J.) and Donald Davis (N.C.) are each co-sponsoring at least one of several proposed bills that would limit regulators’ ability to negotiate down prices of drugs covered by the Medicare government insurance program. The legislation would erode the drug-pricing reforms included in the Democrats’ 2022 Inflation Reduction Act — efforts that Peters, Nickel, and Gottheimer supported. (Davis had not yet been elected to Congress.)
The four, who all hail from states with a major biotech or drug-industry presence, have together raked in more than $300,000 from pharmaceutical and health-products interests during the 2023-2024 congressional session. Gottheimer is reportedly eyeing a 2025 gubernatorial run in New Jersey, home to the pharmaceutical giant Merck & Co.
Recent Posts
House Bill Would Let Marco Rubio Strip Passports Over Political Speech
Take Action Now Provision would let the Secretary of State deny or revoke passports over alleged “material support” as critics warn of thought…
Targeting Venezuela, Trump Escalates U.S. Campaign Of Aggression In Latin America
Take Action Now The US and Latin American right have long mobilized to remove challenges to their traditional privileges and control.By Jonathan…
GOP-Led Congressional Committee Votes To Block Trump From Rescheduling Marijuana
Take Action Now Can the Trump administration, or any administration, declare people guilty and treat them as criminals, absent the transparent legal…
Never Forget What?
Take Action Now Never forget meant never forgive. Never forget meant someone would pay. And with my Muslim name, my South Asian heritage, I knew who…